What will be the status of midostaurin's domestic launch in 2025?

Midostaurin (Midostaurin) is a tyrosine kinase inhibitor mainly used to treat acute myeloid leukemia (AML) and certain types of cancer. It has shown significant efficacy especially in patients with positive FLT3 mutations. As a targeted therapy drug, midostaurin brings new treatment hope to many AML patients by inhibiting the growth and spread of cancer cells.

Currently, midostaurin is not widely available in the domestic market, but it has been approved and put into use globally, especially in Europe and the United States. Midostaurin was launched in the United States by Novartis and was initially used for the treatment of FLT3 mutation-positive acute myeloid leukemia (AML). With the gradual verification of its clinical efficacy, the drug was approved by the FDA for use in combination with chemotherapy to treat AML patients and achieved significant clinical effects.

Regarding the situation of midostaurin in the Chinese market, although it has not yet been fully launched in the country, as targeted drugs and precision medicine have gradually become new trends in tumor treatment, the prospect of midostaurin entering China is positive. In recent years, China has gradually accelerated the approval of drugs for the treatment of malignant tumors such as leukemia. Therefore, midostaurin may be approved by the Chinese drug regulatory authorities and officially launched before 2025.

Currently, some domestic hospitals and cancer centers may provide patients with midostaurin treatment through clinical trials or imported drug channels, especially for patients with acute myeloid leukemia who have positive FLT3 mutations. This means that although the official launch time has not yet been determined, patients in need can still obtain the drug through specific channels. More clinical data support is needed as to whether midostaurin can be seen in China's medical insurance in the future.

Reference materials:https://medlineplus.gov/druginfo/meds/a617033.html